Herpesvirus antiviral treatment reversed CFS illness in 79 of 106 Group A CFS patients

BY: A Martin Lerner, Safedin Beqaj, James T Fitzgerald,
Ken Gill, Carol Gill, James Edington

Long-term valacyclovir and/or valganciclovir subset-directed administration improved or eliminated CFS symptoms in Group A CFS patients, allowing them to return to normal life.

The present data are remarkable considering that these CFS patients had been ill for a mean of 4.8 years before antiviral therapy was begun. The mean duration of antiviral therapy for Group A CFS patients was 2.4 years. Both valacyclovir and valganciclovir were equally effective in single or multiple herpesvirus CFS subsets.

PS: Group A CFS patients have EBV, HCMV, and HHV6 in single or multiple infection without coinfection.

Group B CFS patients are similar to Group A, but with coinfections, tick-borne Borrelia burgdorferi, Babesia microti, Anaplasma phagocytophila, and/or adult rheumatic fever.